Traditional Vs. Digital: Merck And GSK Battle For HPV Vaccines In China
Executive Summary
In contrast to GSK’s online-to-offline approach to promote its HPV vaccine, Merck is going the conventional route and tapping into the Chinese market via a domestic partner for Gardasil and other vaccines. Its partner Zhifei Biological is accelerating an expansion of its direct sales team to extend its reach.
You may also be interested in...
China Appetite For HPV Vaccine Delivers Surprise For Merck
When Merck realized that demand in China is so large for its HPV vaccine Gardasil, the US company wanted to understand more about the market, but a coordinated pre-launch awareness campaign appears to have helped.
Key Role For China As Sanofi’s Emerging Markets Business Grows
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.